WXXWY WUXI BIOLGCS ADR
- 2.710
- -0.022-0.81%
WUXI BIOLGCS ADR News
Far exceeding the whole year of last year! The Hong Kong stock buyback wave continues, what impact does it have?
Since the beginning of this year, the buyback scale in the Hong Kong stock market has increased significantly. The total repurchase amount has exceeded 180 billion Hong Kong dollars, while the total buyback amount for the whole of last year was over 120 billion Hong Kong dollars.
The大行 (GTJA) has lowered the target price of Wuxi Bio (02269.HK) to 14.6 yuan, while the new item continues to grow.
Guotai Junan issued a research report indicating that considering the geopolitical risks of Wuxi Bio (02269.HK), it revised down its adjusted net profit forecast for the years 2024 to 2026 to CNY 4.919 billion, CNY 5.623 billion, and CNY 6.738 billion, respectively, with earnings per share of CNY 1.18, CNY 1.35, and CNY 1.62. The target price was lowered to CNY 14.6, while maintaining a "shareholding" rating. The bank stated that Wuxi Bio's new projects continue to grow, and its non-COVID-19 business development is stable. The company maintains its full-year guidance for 2024 unchanged. The company will also continue to invest in overseas production capacity construction, with an estimated completion by 20.
September 4th share repurchases | Tencent, Meituan-W, etc. have all announced share repurchases, with Tencent spending 1.003 billion Hong Kong dollars.
According to the disclosure documents of hkex on september 5, tencent and meituan-w repurchased shares. 1. Tencent repurchased 2.69 million ordinary shares on september 4, involving 1.003 billion hong kong dollars, with a repurchase price ranging from 376.4 hong kong dollars to 371.2 hong kong dollars per share. Since the authorization resolution for repurchase was passed, the cumulative repurchase of securities has reached 0.139 billion shares, accounting for 1.474% of the number of shares issued at the time of the ordinary resolution. 2. Meituan-w on september
Stock Opportunity Tracking | Hang Seng Index Company: Newly added fast-inclusion rules to the Hong Kong Stock Connect Index; Autohome plans to repurchase up to 0.2 billion US dollars of shares.
On the same day, the three major internet giants deepened their interconnection; the Beige Book of the Federal Reserve: The number of regions with flat or declining economic activity has increased to 9; Guangdong Inv has obtained a commitment for HKD 3 billion in committed term loan financing.
Wuxi Bio spent HKD 59.8888 million on September 4 to repurchase 5.43 million shares.
Wuxi Bio (02269) announced that on September 4, 2024, the company will spend 59.8888 million Hong Kong dollars to repurchase 5.43 million shares at a repurchase price of HK$10.78-11.20 per share.
Mainland China speeds up the implementation of centralized procurement of new batches of high-value medical consumables based on volume
Shi Zihai, Deputy Director of the National Medical Insurance Administration, recently led a team to Tianjin to investigate the centralized procurement of high-value medical consumables by national institutions. He stated that efforts should be made to accelerate the progress of the new batch of centralized volume-based procurement of high-value medical consumables by national institutions, and to include high-value medical consumables such as cochlear implants in the procurement scope. The market for consumables and clinical characteristics should be fully considered, and a "one product, one strategy" approach should be studied to improve the procurement rules. At the same time, we should focus on the implementation of the fourth batch of consumable procurement and the follow-up procurement of selected results for artificial joints after the expiration of the agreement, to ensure that the selected products are admitted to hospitals in a timely manner, guide and urge medical institutions to give priority to th
On September 3, the buyback pool | Tencent, HSBC Holdings and others have announced buybacks, with Tencent Holdings spending 1.003 billion Hong Kong dollars.
According to the disclosure documents of hkex on September 4, Tencent Holdings (00700.HK), HSBC Holdings (00005.HK), etc. repurchased shares. ① Tencent Holdings (00700.HK) repurchased 2.65 million ordinary shares on September 3, involving an amount of 1.003 billion Hong Kong dollars, with a repurchase price per share ranging from 381.2 Hong Kong dollars to 374.8 Hong Kong dollars. Since the authorization resolution for repurchase, the cumulative repurchased securities amount to 0.136 billion shares, accounting for 1.445% of the number of issued shares when the ordinary resolution was passed. ② HSBC Holdings (00005.HK) on September
Express News | The US House of Representatives plans to review the updated version of the Biodefense Act (H.R.8333) next week.
Express News | Yesterday, 53 Hong Kong stocks were bought back by their respective companies, with tencent, Kuaishou, and Wuxi Bio having the highest repurchase amounts.
Wuxi Bio (2269.HK): Continuous growth in new projects, maintaining full year guidance of 24.
This report summary states that the company is actively promoting its 'winning molecule' global strategy, with new projects exceeding expectations. The non-COVID business is showing good growth momentum, and overseas production capacity continues to be established. We are bullish on the company's long-term development and maintain a 'shareholding' rating. Investment highlights: Maintaining a 'shareholding' rating.
On September 2nd, there was a buyback consortium. Tencent, HSBC Holdings, and others have all initiated buybacks, with Tencent Holdings spending HKD 1.003 billion.
According to the disclosure document of hkex on September 3, Tencent holdings (00700.HK), hsbc holdings (00005.HK) and other companies repurchased shares. ① Tencent Holdings (00700.HK) repurchased 2.65 million shares of common stock on September 2, involving an amount of 1.003 billion Hong Kong dollars, with a repurchase price per share ranging from 383.2 Hong Kong dollars to 376.6 Hong Kong dollars. Since the authorization resolution for repurchase was passed, the cumulative repurchased securities reached 0.134 billion shares, accounting for 1.417% of the number of shares issued when the ordinary resolution was passed. ② HSBC Holdings (00005.HK) in August
Wuxi Bio spent 59.8116 million Hong Kong dollars to repurchase 5.48 million shares on September 2nd.
Wuxi Bio (02269) announced in a statement that on September 2, 2024, the company spent HK$59.8116 million to repurchase 5.48 million shares.
HK Stock Opportunity Tracking | August New Energy Vehicle Performance Released! Xiaomi has exceeded 10,000 for three consecutive months, and Ideal Auto Delivery has increased by 37.8% year-on-year. Miniso plans to repurchase no more than HKD 2 billion sha
Industrial and commercial bank of China's revenue in the first half of the year was 401.999 billion yuan, a decrease of 6.3%; China Construction Bank Corporation's operating income in the first half of the year was 374.831 billion yuan, a decrease of 3.43%; Alibaba spent 59.973 million US dollars to repurchase 5.9226 million shares.
Wuxi Biologics (Cayman): Acquisition Worth $108.5M
Wuxi Biologics (Cayman) to Purchase 30% Equity Interest in WuXi Vaccines
Wuxi Bio (02269) plans to acquire the remaining 30% equity of Wuxi Hyde for 0.1085 billion US dollars.
Wuxi Bio (02269) announced that on August 30, 2024, the company intends to acquire Shanghai Hile Bio-Technology through its subsidiary Wuxi Bio.
Express News | Shanghai Hile Bio-technology plans to pay cash to purchase 55% equity of Shaanxi Ruisheng Bio-technology Co., Ltd.
Wuxi Bio's innovative bioprocess technology platform, WuXiUITM, has successfully completed its first 2000-liter GMP production scale-up.
Wuxi Bio's super-enhanced batch feeding bioprocess platform, WuXiUI, has successfully completed its first GMP production of 2000 liters of biopharmaceutical solution. Compared to conventional batch feeding processes, the output has increased fourfold. This production scale-up fully utilizes Wuxi Bio's self-developed cell culture medium, MagniCHO, in combination with WuXiUI technology, which significantly reduces the overall production cost of the biopharmaceutical solution. The successful scale-up of WuXiUI from small-scale production to 2000 liters GMP production and the achievement of a series of excellent results fully demonstrate the advanced, mature, and stable nature of this technology platform, which can greatly enhance biopharmaceutical production.
Hong Kong stocks soar with the collective rise of CRO concept stocks, as the Federal Reserve is expected to cut interest rates and new industry orders are accelerating recovery.
CRO concept stocks rose collectively, as of the publication, Joinn Laboratories (06127) rose 2.96% to HKD 7.3; Wuxi AppTec (02359) rose 2.56% to HKD 34.05; Asymchem Laboratories (06821) rose 2.5% to HKD 40.95.
Hong Kong Stock Market Closing (08.26) | Hang Seng Index rose 1.06%, pharmaceutical, real estate, non-ferrous stocks rose, Wuxi Bio (02269) leading the blue chips.
Fed Chair Powell sends a strong signal of interest rate cuts, and Hong Kong stocks have rebounded today, with all three major indexes briefly rising more than 1% during trading.
Analysis
Price Target
No Data
